UFP Technologies Q2 Earnings Call Highlights

UFP Technologies (NASDAQ:UFPT) reported second-quarter 2026 sales of $174 million, a 15.1% increase supported by broad-based demand across its medical technology portfolio. Adjusted earnings per share rose 16.8% to $2, establishing a company record. The results show that sales growth and per-share earnings both advanced meaningfully during the quarter, with adjusted EPS growth exceeding the increase in sales. For investors, the breadth of demand across the medical technology portfolio is a central feature of the update. The available information does not identify a single product, customer or market as the primary growth driver, indicating that the reported sales increase was broad-based rather than linked to one specified area. The $2 adjusted EPS result provides a clear profitability benchmark for future quarterly comparisons. Combined with 15.1% sales growth, it presents a positive quarterly snapshot for UFPT, although the reported figures alone do not provide detail on margins, forecasts, customers, orders or other operating metrics. Investors will therefore be focused on whether UFP Technologies can sustain demand across its medical technology portfolio and continue translating sales expansion into earnings growth. Based on the available results, the company’s second quarter was defined by $174 million in sales, double-digit revenue growth and record adjusted EPS.